DADC
PLX icon

D.A. Davidson & Co’s Protalix BioTherapeutics PLX Stock Holding History

D.A. Davidson & Co’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-130,700
Closed -$583K – 1215
2021
Q1 		$583K Buy
+130,700
New +$609K 0.01% 754

Other funds holding PLX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

D.A. Davidson & Co's PLX Position: Q2 2021 in Review

D.A. Davidson & Co sold out of Protalix BioTherapeutics (PLX) in Q2 2021, closing a stake of 130,700 shares — an estimated $583K sold.

D.A. Davidson & Co first reported a position in PLX in Q1 2021 and held it in 1 quarter. The position peaked at $583K in Q1 2021. 33 funds tracked by Wall St. Rank hold PLX as of Q2 2021.

  • D.A. Davidson & Co reported no remaining Protalix BioTherapeutics position as of Q2 2021 after selling out during the quarter.
  • D.A. Davidson & Co sold 130,700 Protalix BioTherapeutics shares in Q2 2021, an estimated $583K.
  • D.A. Davidson & Co first reported a position in Protalix BioTherapeutics in Q1 2021 and held it in 1 quarter.
  • D.A. Davidson & Co's Protalix BioTherapeutics position peaked at $583K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2021.

Based on D.A. Davidson & Co's 13F filing for Q2 2021, filed 10 Aug 2021.